about
Osteoimmunology and the influence of pro-inflammatory cytokines on osteoclastsTreatment with low-dose atorvastatin, losartan, and their combination increases expression of vasoactive-related genes in rat aortasIncreased phosphatidylethanolamine N-methyltransferase gene expression in non-small-cell lung cancer tissue predicts shorter patient survival.Association between 11beta-hydroxysteroid dehydrogenase type 1 gene polymorphisms and metabolic syndrome in Bosnian population.Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture.The many faces of estrogen signaling.Molecular mechanisms of insulin resistance and associated diseases.Impact of metformin and rosiglitazone treatment on glucose transporter 4 mRNA expression in women with polycystic ovary syndrome.The relationship between osteoclastogenic and anti-osteoclastogenic pro-inflammatory cytokines differs in human osteoporotic and osteoarthritic bone tissues.ADRA2A is involved in neuro-endocrine regulation of bone resorption.Organic anion transporting polypeptides OATP1B1 and OATP1B3 and their genetic variants influence the pharmacokinetics and pharmacodynamics of raloxifeneEtidronate does not suppress periprosthetic bone loss following cemented hip arthroplasty.The Pleiotropic Effects of Atorvastatin on Stable Angina Patients: Evidence by Analysis of High-Density Lipoprotein Size and Subclasses, and Plasma mRNA.Risk factors for symptomatic osteonecrosis in childhood ALL: A retrospective study of a Slovenian pediatric ALL population between 1970 and 2004.Effects of UGT1A1*28 polymorphism on raloxifene pharmacokinetics and pharmacodynamics.Opposite effects of GSTM1--and GSTT1: gene deletion variants on bone mineral density.The antioxidant enzyme GPX1 gene polymorphisms are associated with low BMD and increased bone turnover markers.New insights into adipose tissue dysfunction in insulin resistance.Epigenetic mechanisms in bone.Bone microRNAs and aging.Genome-wide gene expression profiling of low-dose, long-term exposure of human osteosarcoma cells to bisphenol A and its analogs bisphenols AF and S.Hypoxia mimetic deferoxamine influences the expression of histone acetylation- and DNA methylation-associated genes in osteoblasts.Influence of trypsinization and alternative procedures for cell preparation before RNA extraction on RNA integrity.P4 medicine and osteoporosis: a systematic review.Raloxifene pharmacodynamics is influenced by genetic variants in the RANKL/RANK/OPG system and in the Wnt signaling pathway.Arsenic trioxide (ATO) influences the gene expression of metallothioneins in human glioblastoma cells.A microarray based identification of osteoporosis-related genes in primary culture of human osteoblasts.MiR-148a the epigenetic regulator of bone homeostasis is increased in plasma of osteoporotic postmenopausal women.Prenatal mercury exposure, neurodevelopment and apolipoprotein E genetic polymorphism.Is laboratory medicine ready for the era of personalized medicine? A survey addressed to laboratory directors of hospitals/academic schools of medicine in Europe.Implementation of a companion diagnostic in the clinical laboratory: the BRAF example in melanoma.Increased plasma levels of CATS mRNA but not CATB mRNA in patients with coronary atherosclerosis.XbaI polymorphism of the estrogen receptor alpha gene influences the effect of raloxifene on the endothelial function.Monitoring of imatinib targeted delivery in human leukocytes.Osteoarthritic versus osteoporotic bone and intra-skeletal variations in normal bone: evaluation with µCT and bone histomorphometry.-1227C>T polymorphism in the pleiotrophin gene promoter influences bone mineral density in postmenopausal women.Optimization of single-stranded conformation polymorphism (SSCP) analysis for screening for the estrogen receptor-alpha gene polymorphism P325P.No major effect of estrogen receptor beta gene RsaI polymorphism on bone mineral density and response to alendronate therapy in postmenopausal osteoporosis.Sequence variations in the osteoprotegerin gene promoter in patients with postmenopausal osteoporosis.Increased levels of osteoprotegerin in hemodialysis patients.
P50
Q26828486-A1EC7B4D-90E2-46C5-A054-A8B71E3427B9Q28577025-2CA965D5-C1E9-4581-8670-3C8C9AAA81B8Q33727484-6ACE0635-48CF-4D5F-BD5F-86E0A6A8228DQ33773181-2E1BB506-CC6C-4740-BA76-DCECB74B4B78Q34268288-30AEDD9D-4A92-48AD-8CE8-E4F2DA32D819Q34408630-A49308B6-BA9C-4821-9ADC-733644A61955Q34563946-29F8ADB1-BD9D-47D4-8204-C9F7B4EAD531Q34759058-CCB4F33E-30E0-4517-8D81-79065EEF9B51Q35838186-12F799CE-9AC4-4DE1-A3AE-EDA0CC7CE18BQ35879492-BC803537-6779-4B79-867E-F28BF54FF6ACQ36334805-F519560F-4BD3-4235-9168-49E9CC1A3BCDQ36440568-5255AC55-0759-4BA4-A34B-6B938C73389BQ37041300-BEF133CD-E1D1-41A6-AA5B-B572A253FC9CQ37106645-628A1076-17B4-42C8-B133-816315F1C8A6Q37184435-AA54DF2F-4A81-453D-9E2B-EAA83CD97196Q37304633-EA722F8E-0176-454D-9157-CF2DC0318761Q37329196-9FF18CD4-7011-450C-9E6E-9C27CDCD1271Q37926599-712C4192-22E7-4985-8F13-1C2B9A5D9E1AQ38172475-5A9F4E86-AD4A-4D51-869B-3CE59934331AQ38761133-5A9B8297-A1A8-43DE-97A8-C8C3A0E5B44AQ38882369-3506FD85-A8F7-4E97-BE74-5E298CEEAB24Q38910456-EAB1D465-0A10-45FA-8C80-4FA438F283F2Q38979116-CA8A55E3-7B30-4A98-975A-BD223DF5DD76Q39016223-1C50019A-CAB1-424A-9CAB-80F1B31E15B3Q39234501-28FB80A7-3E62-411B-9A9B-61C6C9A4A324Q39354070-AE3D546A-16B8-40B0-A15A-E5AB426AA049Q39795173-34C0BCAF-0DF1-414C-882A-CE52A00BAFCAQ40449980-5BEBEB6C-7866-4328-8D51-68148DA13C10Q40586334-BB7A9289-51DD-4B8C-8BBD-D8721DCC577AQ40877276-F13F563F-290F-4E75-80EF-15EBE44D62DCQ41749375-58925A18-2D7D-404A-ABCC-8ABF4B9F4976Q42873585-E386AB20-F3D5-4CCE-9158-F019C445A68AQ42977785-E004B012-F72B-46E1-889F-23052BAE735DQ43585487-1B28A191-E632-4C9D-9134-388FC8AFDF44Q43603196-BD68DF11-CE1C-4CB0-BBEA-EB820DF451D3Q43711856-D7145B6D-C10E-4EEB-A2AE-A8A95BD0705BQ43719380-6C123060-AB4E-4D19-B2E7-6B4526F4EC60Q44076951-1B04F248-BD51-4F7E-9808-6A2C05DFFE77Q44237348-9880A2CE-5C4D-48BC-854B-B6042F2D5D10Q44245391-4609D5D4-3BC2-4F70-BDC4-632FF1366ADF
P50
description
hulumtuese
@sq
researcher
@en
ricercatrice
@it
wetenschapper
@nl
հետազոտող
@hy
name
Janja Marc
@ast
Janja Marc
@en
Janja Marc
@es
Janja Marc
@nl
Janja Marc
@sl
type
label
Janja Marc
@ast
Janja Marc
@en
Janja Marc
@es
Janja Marc
@nl
Janja Marc
@sl
prefLabel
Janja Marc
@ast
Janja Marc
@en
Janja Marc
@es
Janja Marc
@nl
Janja Marc
@sl
P214
P106
P21
P214
P31
P496
0000-0001-6013-9758
P734
P735
P7859
viaf-305703808